Analysts Set MiMedx Group, Inc (NASDAQ:MDXG) Target Price at $8.50

Shares of MiMedx Group, Inc (NASDAQ:MDXG) have earned a consensus rating of “Moderate Buy” from the seven brokerages that are currently covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a sell rating and six have issued a buy rating on the company. The average 12-month target price among brokers that have updated their coverage on the stock in the last year is $8.50.

Several equities analysts recently issued reports on the company. Wall Street Zen cut MiMedx Group from a “buy” rating to a “hold” rating in a research report on Saturday, May 2nd. Craig Hallum reduced their target price on MiMedx Group from $10.00 to $7.00 and set a “buy” rating for the company in a report on Friday, April 17th. Weiss Ratings cut MiMedx Group from a “sell (d+)” rating to a “sell (d)” rating in a research note on Monday, May 18th. Finally, Citizens Jmp lowered their price target on MiMedx Group from $7.00 to $6.00 and set a “market outperform” rating on the stock in a report on Thursday, April 30th.

Hedge Funds Weigh In On MiMedx Group

Hedge funds have recently bought and sold shares of the business. Nantahala Capital Management LLC purchased a new stake in shares of MiMedx Group during the 3rd quarter valued at about $10,237,000. Marshall Wace LLP raised its holdings in shares of MiMedx Group by 864.9% during the fourth quarter. Marshall Wace LLP now owns 1,381,288 shares of the company’s stock valued at $9,351,000 after purchasing an additional 1,238,132 shares during the last quarter. Hillsdale Investment Management Inc. bought a new position in MiMedx Group during the fourth quarter valued at approximately $7,134,000. Disciplined Growth Investors Inc. MN lifted its position in MiMedx Group by 283.0% during the third quarter. Disciplined Growth Investors Inc. MN now owns 1,383,451 shares of the company’s stock valued at $9,656,000 after purchasing an additional 1,022,202 shares during the period. Finally, Paradigm Capital Management Inc. NY boosted its holdings in MiMedx Group by 39.1% in the first quarter. Paradigm Capital Management Inc. NY now owns 3,410,300 shares of the company’s stock worth $13,471,000 after purchasing an additional 959,100 shares during the last quarter. Hedge funds and other institutional investors own 79.15% of the company’s stock.

MiMedx Group Stock Up 1.7%

Shares of MiMedx Group stock opened at $4.20 on Thursday. The company has a 50-day simple moving average of $3.86 and a two-hundred day simple moving average of $4.31. The stock has a market capitalization of $625.59 million, a PE ratio of 21.00 and a beta of 1.45. MiMedx Group has a 52-week low of $3.03 and a 52-week high of $7.99. The company has a debt-to-equity ratio of 0.07, a quick ratio of 4.81 and a current ratio of 5.39.

MiMedx Group (NASDAQ:MDXG) last posted its quarterly earnings results on Wednesday, April 29th. The company reported ($0.05) EPS for the quarter, beating analysts’ consensus estimates of ($0.07) by $0.02. The firm had revenue of $58.99 million for the quarter, compared to analysts’ expectations of $65.80 million. MiMedx Group had a net margin of 7.88% and a return on equity of 21.03%. On average, analysts anticipate that MiMedx Group will post -0.09 EPS for the current fiscal year.

MiMedx Group Company Profile

MiMedx Group, Inc is a biopharmaceutical company focused on the development, manufacture and marketing of regenerative biomaterial products derived from human placental tissues. The company’s core mission centers on harnessing the extracellular matrix and growth factors within amniotic and chorionic membranes to support wound healing and surgical applications. MiMedx’s product line leverages proprietary purification processes designed to retain native tissue properties while ensuring sterility and safety.

MiMedx’s principal offerings include amnion/chorion allografts branded under names such as EpiFix® and AmnioFix®, which are indicated for the treatment of acute and chronic wounds—including diabetic foot ulcers, venous leg ulcers and surgical site repair.